Association of pretreatment serum interferon inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C
about
Lack of response to exogenous interferon-α in the liver of chimpanzees chronically infected with hepatitis C virusRole of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infectionPredictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infectionVasculitic syndromes in hepatitis C virus: A review.Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response.Inducible protein-10 as a predictive marker of antiviral hepatitis C treatment: A systematic review.Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response.Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferonThe role of chemokines in the recruitment of lymphocytes to the liver.Gene expression profiling of dengue infected human primary cells identifies secreted mediators in vivo.Ribavirin improves early responses to peginterferon through improved interferon signalingThe CXCR3(+)CD56Bright phenotype characterizes a distinct NK cell subset with anti-fibrotic potential that shows dys-regulated activity in hepatitis CChemokine antagonism in chronic hepatitis C virus infectionImpact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infectionQuantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment responseInterferon γ-induced protein 10 kinetics in treatment-naive versus treatment-experienced patients receiving interferon-free therapy for hepatitis C virus infection: implications for the innate immune response.Relevance of baseline viral genetic heterogeneity and host factors for treatment outcome prediction in hepatitis C virus 1b-infected patientsPlasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infectionDanoprevir monotherapy decreases inflammatory markers in patients with chronic hepatitis C virus infection.Clinical implications of chemokines in acute and chronic hepatitis C virus infection.Serum IP-10 Levels Correlate with the Severity of Liver Histopathology in Patients Infected with Genotype-1 HCV.The Impact of IL28B Genotype and Liver Fibrosis on the Hepatic Expression of IP10, IFI27, ISG15, and MX1 and Their Association with Treatment Outcomes in Patients with Chronic Hepatitis C.Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy.Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection.Predictive factors associated with hepatitis C antiviral therapy response.Chemokine CXCL10 at week 4 of treatment predicts sustained virological response in patients with chronic hepatitis C.Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infectionEffector CD8 T cell trafficking within the liverAssociation of IL28B Genotypes and Baseline Serum Interferon-γ-Inducible- Protein-10 Levels with Treatment Response in Hepatitis C Virus Patients in China.The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection.Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C.Retreatment of chronic hepatitis C in previous non-responders and relapsers.Dynamic interplay between CXCL levels in chronic hepatitis C patients treated by interferon.B-Cell Activating Factor Belonging to the Tumor Necrosis Factor Family and Interferon-γ-Inducible Protein-10 in Autoimmune Hepatitis.Anti-inflammatory cytokines, pro-fibrogenic chemokines and persistence of acute HCV infectionSustained virologic response to peginterferon alpha-2a and ribavirin in 335 patients with chronic hepatitis C: a tertiary care center experience.Cellular and molecular interactions in coinfection with hepatitis C virus and human immunodeficiency virus.Management of nonresponsive hepatitis C.Mixing the right hepatitis C inhibitor cocktail.
P2860
Q27486088-61EED83A-F9F3-431B-962F-4791077FD444Q27490393-8FAD6295-E624-4F61-91EA-CEC1F34ED7D5Q27490866-C6247B9C-B808-4A53-8CDA-C84D92AFE5FFQ29615959-72BF7088-F73B-42F0-A981-443761270104Q30238653-EA4CB301-2DFA-41E9-95B6-CC57E87AAFE7Q33597579-2DF9083B-0B82-4115-8513-7106045869ABQ33706737-8B41E909-8F81-49A5-8DCC-CAE45F809161Q33816657-AF2A31D2-6B3A-4970-9621-1C270AC6D667Q33877898-261FEC0F-F989-453C-B834-C77EA420E9B0Q33906565-36BA2868-3C5F-4B62-8F52-5A62578BD510Q33945948-8BB53F9B-D930-434A-879F-99D5DC393BB2Q33987120-198A1F34-9B21-48E4-9782-2EB5B14F4867Q34335634-AB82C9E7-204D-48F0-B2EC-2FF1D713F793Q34429056-D3EF02F5-7823-4E17-A032-0648E3074298Q34599847-F63F1ADD-5E8F-484B-8169-5B93FA5B2C96Q34867045-DB16B256-7010-47AC-A48E-D03E08884FE9Q34974790-4C4A21A3-F700-4AC1-9392-885B95D2E65DQ34981566-7D24F2D4-6286-4E58-B06B-C6889A3E7B2CQ35053399-B04322AD-EF8A-4562-9536-689B0DAFF241Q35065912-9A5455A2-CB3F-4923-BFF6-0253C2BFE41CQ35561908-23958936-2025-489C-A87F-CFC285B96042Q35619177-6D9BB469-D142-4384-99BD-4C4785D8E71DQ35675852-636FF94B-C25D-4658-BB50-953C85D79685Q35693436-2A9A18FD-FEDE-4FDD-86CA-1F00BA9A4404Q35764450-FC7EE9BC-A9DA-4A7E-8D0F-68C1CDF7B6B9Q35790397-000BB674-2052-449F-AC03-F0D84D6D7968Q36172970-D82E123E-92C9-4D7E-AB51-CCC331E529B4Q36611680-9AF926B8-EFF8-4013-B923-17B8DB05AD92Q36625986-228127E7-9C64-4CE9-8BC6-4B3B28CC822AQ36848968-1047F415-8230-441B-A0AC-3254F1CC1779Q36944050-C70276B5-37E4-4B90-A1EB-BD26A8BA0F32Q36964114-1237AE2E-C289-44C3-9D98-F19E6EE2E9F3Q36968144-6EBE6E40-E74B-43A1-BD62-505C6B52989FQ37000796-5308D71A-F38D-4C46-A347-99D20FC42468Q37205477-DEDB63E1-50DD-48BE-8F6C-506F793EB262Q37222199-32B9C24C-DED7-43A8-8FAC-EAD2A119F15CQ37243555-1BCF1E62-F01E-4D4E-B8D5-82B2DB84F513Q37301305-E2DC6121-C0A1-49CA-8816-E26B4788D840Q37727164-2E2AD6E0-A594-4BBE-95C4-0754941473E3Q37812189-D7541628-8F40-4896-8F76-96137A89B7D7
P2860
Association of pretreatment serum interferon inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Association of pretreatment se ...... ients with chronic hepatitis C
@ast
Association of pretreatment se ...... ients with chronic hepatitis C
@en
Association of pretreatment se ...... ients with chronic hepatitis C
@nl
type
label
Association of pretreatment se ...... ients with chronic hepatitis C
@ast
Association of pretreatment se ...... ients with chronic hepatitis C
@en
Association of pretreatment se ...... ients with chronic hepatitis C
@nl
prefLabel
Association of pretreatment se ...... ients with chronic hepatitis C
@ast
Association of pretreatment se ...... ients with chronic hepatitis C
@en
Association of pretreatment se ...... ients with chronic hepatitis C
@nl
P2093
P2860
P356
P1433
P1476
Association of pretreatment se ...... ients with chronic hepatitis C
@en
P2093
C García-Monzón
G Castellano
I Fernández
J García-Samaniego
O L Iacono
P2860
P356
10.1136/GUT.2005.074062
P407
P577
2006-03-01T00:00:00Z